Navigation Links
Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
Date:8/9/2012

BLUE BELL, Pa., Aug. 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2012.

Total revenue was $436,000 and $2.1 million for the three and six months ended June 30, 2012, compared to $2.4 million and $5.5 million for the same periods in 2011.

Total operating expenses were $7.2 million and $13.1 million for the three and six months ended June 30, 2012, compared to $7.6 million and $15.0 million for the same periods in 2011.

The net loss attributable to common stockholders for the three and six months ended June 30, 2012, was $4.1 million, or $0.03 per share, and $12.4 million, or $0.09 per share, as compared with a net loss attributable to common stockholders of $2.8 million, or $0.02 per share, and $5.2 million, or $0.04 per share, for the three and six months ended June 30, 2011.

Revenue The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $234,000 and $1.7 million for the three and six months ended June 30, 2012, versus $1.7 million and $4.5 million for the same periods in 2011. This NIAID contract, which exceeds $23 million over five years (plus two additional option years), is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for the three and six months ended June 30, 2012, were $4.5 million and $8.6 million for the three and six months ended June 30, 2012 as compared to $4.5 million and $8.9 million for the same periods in 2011. General and administrative expenses for the three and six months ended June 30, 2012 were $2.7 million and $5.2 million versus $3.1 million and $6.4 million for the same periods in 2011.

Net Loss Attributable to Common St
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
3. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
4. Inovio Pharmaceuticals to Present at JMP Investor Conference
5. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
6. Inovio Pharmaceuticals to Present at SPI 2012
7. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
10. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
11. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... clinical studies evaluating potential new medicines in the ... upcoming 2014 European Society of Medical Oncology (ESMO) ... Spain . Data being presented include results ... and efficacy of veliparib (ABT-888), a poly (adenosine ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... SILVER SPRING, Md., March 25, 2011 The U.S. Food ... patients with late-stage (metastatic) melanoma, the most dangerous type ... ) Melanoma is the leading cause ... cases of melanoma were diagnosed in the United States ...
... CoreLab Partners, Inc , the global entity resulting ... is set to attend and actively participate in several ... two weeks. "The legacy of our organization ... physicians, scientists and operational personnel have provided to the ...
Cached Medicine Technology:FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 2FDA Approves New Treatment for a Type of Late-Stage Skin Cancer 3CoreLab Partners Collaborates at Worldwide Industry Conferences 2
(Date:9/22/2014)... SANTA CLARA, Calif.– Health 2.0 8th ... Healthline , a leading provider of intelligent ... HealthData Engine to harness the power ... and reduce costs. The new big data analytics ... advanced clinical natural language processing (NLP) technologies and ...
(Date:9/22/2014)... 22, 2014 The Advocator Group, LLC— ... its partnership with the RxCut® pharmacy savings program, which ... and employees. The company looks forward to offering prescription ... the ways in which they deliver on the goal ... by Free For All® Inc., the RxCut® ...
(Date:9/22/2014)... Tristar Products, Inc. is celebrating the ... known as the 'Godfather of Fitness,' with the release ... September 24th at the TriBeCa Film Center® in New ... behind the man whose mission was to show the ... The name of the film is derived from one ...
(Date:9/22/2014)... estimated 1.68 to 3.8 million sports-related concussions occur in ... a significant number that go unreported. Current Concepts ... of Neurosurgery , official journal of ... Gail Rosseau, MD, the lead guest editor, is well ... prevention, and serves on the Board of Directors of ...
(Date:9/22/2014)... Research reveals that the body’s supply ... declines during the aging process. This decline allows the ... as wrinkles, droopy skin, weakened muscles and loss of ... Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I ... the aging process. , Decades of scientific research ...
Breaking Medicine News(10 mins):Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 2Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 3Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 4Health News:Healthline’s New HealthData Engine Turns Unstructured Data Into Actionable Insights 5Health News:The Advocator Group, LLC Announces Partnership with Pharmacy Savings Program RxCut® 2Health News:The Advocator Group, LLC Announces Partnership with Pharmacy Savings Program RxCut® 3Health News:Tristar Products Premieres The Jack LaLanne Documentary at TriBeCa Film Center in New York City 2Health News:Tristar Products Premieres The Jack LaLanne Documentary at TriBeCa Film Center in New York City 3Health News:Neurosurgery tackles past, current and future concepts of sports concussion 2Health News:Neurosurgery tackles past, current and future concepts of sports concussion 3Health News:Neurosurgery tackles past, current and future concepts of sports concussion 4Health News:Diet Doc Reveals the Secret to Looking and Feeling Younger with new Prescription Sermorelin hGH Anti-Aging Therapy 2Health News:Diet Doc Reveals the Secret to Looking and Feeling Younger with new Prescription Sermorelin hGH Anti-Aging Therapy 3
... could help prevent complications for pregnant women with the ... the 20th week of pregnancy and is characterized by ... the urine. In severe cases it can lead to ... the mother to suffer a series of potentially fatal ...
... embryo transfer instead of a double embryo transfer during ... births without substantially lowering live births, // according to ... than 36 and compared the two approaches of in ... at least one live birth and rates of multiple ...
... nearly 15 million people worldwide. Problems with a ... sneezing, laughing, or lifting heavy objects. Austrian researchers ... with their own stem cells, which they say ... involves removing stem cells from a patient's arm, ...
... that stem cell therapy is effective in treating pigs ... cells from one pig's bone marrow and injecting them ... heart's function to its original condition. ,Researchers studied ... and half of them received therapy. They found injecting ...
... According to a recent study researchers say autistic boys with ... suffering from a language-related disorder known as Specific Language Impairment ... specialists better understand autism and how to choose the best ... MRI scans to look at Broca’s area -- a key ...
... new study the healthiest environment for your child at bedtime ... at night may put children at risk for leukemia.// ... night workers and an increased risk for breast cancer, further ... factor for leukemia. ,Researchers have determined that light at ...
Cached Medicine News:
... Sun Med TruFlow™ Oxygen flowmeter with a ... warranty covering calibration and manufacturing defects. A ... meet most needs. Also available with all ... power take-off and double unit configurations. Our ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: